Castle Biosciences, Inc. (CSTL)

Castle Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	332.07	219.79	137.04	94.09	62.65
Revenue Growth (YoY)	51.09%	60.38%	45.65%	50.18%	20.79%
Cost of Revenue	60.21	44.98	32.01	15.82	9.69
Gross Profit	271.86	174.81	105.03	78.26	52.96
Selling, General & Admin	200.05	180.15	143	86.74	48.13
Research & Development	52.04	53.62	44.9	29.65	13.26
Operating Expenses	263.19	242.78	196.17	118.34	61.39
Operating Income	8.67	-67.98	-91.14	-40.08	-8.42
Interest Expense	-0.58	-0.01	-0.02	-0	-2.63
Interest & Investment Income	12.92	10.62	3.97	0.07	0.37
EBT Excluding Unusual Items	21.01	-57.37	-87.19	-40.01	-10.69
Gain (Loss) on Sale of Investments	0.56	-	-	-	-
Other Unusual Items	-	-	18.29	-	0.49
Pretax Income	21.56	-57.37	-68.9	-40.01	-10.2
Income Tax Expense	3.32	0.1	-1.77	-8.72	0.08
Net Income	18.25	-57.47	-67.14	-31.29	-10.28
Net Income to Common	18.25	-57.47	-67.14	-31.29	-10.28
Shares Outstanding (Basic)	28	27	26	25	19
Shares Outstanding (Diluted)	29	27	26	25	19
Shares Change (YoY)	9.15%	2.87%	3.65%	32.80%	118.63%
EPS (Basic)	0.66	-2.14	-2.58	-1.24	-0.54
EPS (Diluted)	0.62	-2.14	-2.58	-1.24	-0.54
Free Cash Flow	36.54	-19.25	-47.29	-22.47	5.11
Free Cash Flow Per Share	1.25	-0.72	-1.81	-0.89	0.27
Gross Margin	81.87%	79.53%	76.64%	83.18%	84.54%
Operating Margin	2.61%	-30.93%	-66.51%	-42.60%	-13.45%
Profit Margin	5.49%	-26.15%	-48.99%	-33.26%	-16.41%
Free Cash Flow Margin	11.00%	-8.76%	-34.51%	-23.88%	8.16%
EBITDA	24.67	-55.65	-80.6	-36.67	-7.95
EBITDA Margin	7.43%	-25.32%	-58.81%	-38.98%	-12.69%
D&A For EBITDA	16	12.33	10.54	3.41	0.47
EBIT	8.67	-67.98	-91.14	-40.08	-8.42
EBIT Margin	2.61%	-30.93%	-66.51%	-42.60%	-13.45%
Effective Tax Rate	15.39%	-	-	-	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q